Next Article in Journal
Does Vitamin B6 Act as an Exercise Mimetic in Skeletal Muscle?
Previous Article in Journal
Myxedema in Both Hyperthyroidism and Hypothyroidism: A Hormetic Response?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 18
10.3390/ijms25189961
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

1-L Transcription in Prion Diseases

by
Jozef Nahalka
1,2
1
Centre for Glycomics, Institute of Chemistry, Slovak Academy of Sciences, Dubravska Cesta 9, SK-84538 Bratislava, Slovakia
2
Centre of Excellence for White-Green Biotechnology, Slovak Academy of Sciences, Trieda Andreja Hlinku 2, SK-94976 Nitra, Slovakia
Int. J. Mol. Sci. 2024, 25(18), 9961; https://doi.org/10.3390/ijms25189961
Submission received: 22 May 2024 / Revised: 17 July 2024 / Accepted: 13 September 2024 / Published: 15 September 2024
(This article belongs to the Special Issue Genomic Research in Neurobiology)
Browse Figures
Versions Notes

Abstract

:
Understanding the pathogenesis and mechanisms of prion diseases can significantly expand our knowledge in the field of neurodegenerative diseases. Prion biology is increasingly recognized as being relevant to the pathophysiology of Alzheimer’s disease and Parkinson’s disease, both of which affect millions of people each year. This bioinformatics study used a theoretical protein-RNA recognition code (1-L transcription) to reveal the post-transcriptional regulation of the prion protein (PrPC). The principle for this method is directly elucidated on PrPC, in which an octa-repeat can be 1-L transcribed into a GGA triplet repeat RNA aptamer known to reduce the misfolding of normal PrPC into abnormal PrPSc. The identified genes/proteins are associated with mitochondria, cancer, COVID-19 and ER-stress, and approximately half are directly or indirectly associated with prion diseases. For example, the octa-repeat supports CD44, and regions of the brain with astrocytic prion accumulation also display high levels of CD44.

1. Introduction

1-L transcription is a recently introduced and very simple bioinformatics method [1,2,3,4,5] that uses a theoretical protein–RNA recognition code [6,7]. This method is based on the principle that RNA binding proteins (RBPs) use at least one amino acid sequence that can be 1-L transcribed into the exact nucleotide sequence of the recognized RNA. 1-L transcription can thus be used to identify genes/proteins that are post-transcriptionally regulated by the RBP. To illustrate the 1L transcription method, the alignment of 1-L transcribed RBP GEMIN5 (gem nuclear organelle associated protein 5) and RNU2-1 (U2 spliceosomal RNA) was presented recently as an example of such an RBP [1].
Liquid–liquid phase separation (LLPS) has emerged as a mechanism for the dynamic and reversible assembly of ribonucleoprotein complexes and is a major factor in the mesoscale organization of proteins and RNAs. Consequently, the misregulation of biomolecular condensates leads to the formation of insoluble aggregates in several neurodegenerative diseases [8]. The sequence-specific RBP–RNA interactions are generally maintained inside the condensates [9]. RNA molecules are increasingly recognized as important factors contributing to ‘prion behavior’ [10]. For example, the prion protein (PrPC) interacts with and acts as a “chaperone” for HIV-1 genomic RNA [11]. More recently, PrPC was shown to have antiviral activity against infection with Japanese encephalitis virus and may also be a promising therapeutic target for flavivirus infections (e.g., Zika virus, dengue virus, yellow fever virus) [12]. Interestingly, it was reported 15 years ago that an RNA aptamer (and to a much lesser extent DNA aptamer) possessing four GGA triplet repeats (R12) could reduce the PrPC aggregation level in mouse neuronal cells that were persistently infected with a transmissible spongiform encephalopathy agent [13]. Two lysine-rich sequences in PrPC (Lys-rich 1/2) were identified as binding sites for R12 and provide the electrostatic interaction between the uniquely arranged phosphate groups of R12 and the lysine clusters of peptides [14]. The interaction between Lys-rich 2 and R12 was studied and deposited in the protein data bank (2RSK, Figure 1A) [13]. The LLPS of PrPC is regulated by the octa-repeat domain independently of histidine residues and copper [15], while sequence-specific RBP–RNA interactions are generally maintained inside condensates [9]. Hence, the octa-repeat domain is important not only for the LLPS, but also for the specific protein-RNA recognition of PrPC (Figure 1A).
During the evolution of the genetic code in the early prebiotic stage, there was likely a stereo-chemical era involving direct interactions between RNA nucleotides and peptide amino acids. In theory, this has been performed in LLPS condensates. Following the crystal structure of aminoacyl transfer RNA synthetases that interact with tRNA, it was proposed the protein–RNA recognition code could be derived from the present genetic code [6]. The principle of the protein–RNA recognition code is explained in Figure 1B and is depicted in the crystal structure of ribosomal release factor 1 (RF1), which interacts with P-site tRNA (4V63). In the type I release factors of all organisms, glutamine 230 in the GGQ motif (a universally conserved motif) contributes directly to peptidyl-tRNA hydrolysis and translation termination on the 70S ribosome [16]. Q230, which has a CAA codon, recognizes and interacts with the C2452A2451 of rRNA and the terminal adenine of tRNA [16]. In the RF1 of Thermus thermophilus, in addition to Q230, the proline 227 (P227) and NTT (asparagine–threonine–threonine) motif help to recognize the CCA-end of tRNA (Figure 1B). The CCA76 readout is performed using the CC and CA readout-2-letter code (2-L), or using the C plus C plus A readout-1-letter code (1-L), as proposed earlier [6,7]. As shown in Figure 1B, the readout of the RNA by the peptide can occur in both directions: N to C, and C to N. In PrPC, an octa-repeat composed of glycine residues overlapped by histidine and glutamine residues can be 1-L transcribed into the GGA RNA repeat motif (Figure 1A). Unsurprisingly, the R12 GGA aptamer was identified as a ligand that reduces the level of PrPC aggregation in mouse neuronal cells infected with transmissible spongiform encephalopathy [13]. Interestingly, the same GGQ amino acid motif was proposed for the recognition of ribose in prebiotic history, with ribose being the sugar component of RNA [17]. It is also interesting that lysine and asparagine in the Lys-rich sequences of PrPC (Figure 1A) have AAA/G and AAT/C codons, respectively. Polyadenosine RNA has been proposed as a possible agent that increases PrPC aggregation [18]. In summary, sequence-specific RBP–RNA interactions in neurons are maintained inside LLPS-condensates [9] and preserve the protein-RNA recognition code [6]. Moreover, more than 1300 proteins present in the lysate of human neurons were found to be maintained in a soluble and functional state by associating with endogenous RNA, since RNA degradation invariably leads to protein aggregation. The majority of these proteins lack conventional RNA-binding domains [19].
The prion disease-associated transmissible agent was named as a ‘prion’ (proteinaceous infectious) particle because it appeared to be devoid of any nucleic acid and consisted of aggregated protein only. Clinical symptoms of prion diseases include rapid cognitive decline and death, often within months [20]. The PrPC protein is encoded by the PRNP gene. Prion diseases are associated with rare mutations of the PRNP gene (genetic forms) or rare transmission of the prion protein between humans and mammals (acquired forms). They can occur spontaneously (sporadically), with sporadic Creutzfeldt–Jakob disease (sCJD) being the most common form in humans. Although prion diseases are relatively rare, understanding their pathogenesis and mechanisms may significantly enhance knowledge in the field of neurodegenerative diseases. Indeed, prion biology is increasingly recognized as being relevant to the pathophysiology of Alzheimer’s disease and Parkinson’s disease, both of which affect millions of people every year [20].
Prion diseases are caused by the misfolding of a normal α-helix-rich protein called cellular prion protein (PrPC) into an abnormal β-sheets-rich protein called PrPSc, which then forms a self-replicating protofibril (PrPfibril) core (Figure 2A). PrPfibril serves as a template for native PrPC to form into PrPSc, which is stabilized by a disulfide bond and collects into amyloid fibril-aggregate plaques in vivo that are detergent/protease-resistant [21,22]. Prion particles in the brain replicate in both astrocytes and neurons [23], whereas microglia are involved in the clearance of PrPSc/PrPfibril during early preclinical stages. During the late preclinical stage, the target of microglial activity shifts from PrPSc uptake to the engulfment of neurons. This transition in microglial phagocytic behavior is followed by the rapid accumulation of PrPSc [24].
PrPC is a glycoprotein that exists in both membrane- and non-membrane-bound forms. It contains five glutamine/histidine-containing octa-peptide repeats (residues 51–91), an LLPS core (residues 91–114) and an α-helice-globular domain (residues 128–230) (Figure 2B). In healthy tissues, α/β/γ-cleavage of PrPC results in signaling (Figure 2B). For example, the N1-fragment has a neuroprotective role by acting as a ligand for G protein-coupled receptor signaling in Schwann cells to support myelin maintenance, while also causing anti-apoptotic effects by activating p53 [25]. PrPC is a GPI (glycosylphosphatidylinositol)-anchored protein that has an N-terminal signal peptide for ER localization and a C-terminal signal peptide for the attachment of GPI [26]. When PrPC is GPI-anchored, the metalloprotease ADAM10 can release nearly full-length PrPC, referred to as “shed-PrP”, into the extracellular space [25]. However, the physiological roles of shed-PrP are yet to be fully studied. The LLPS of the mammalian prion protein is mainly driven by its LLPS-core. However, the ability to undergo LLPS has evolved with the octa-repeat in the intrinsically disordered domain, independently of the histidine residues [15]. Moreover, the histidine residues can be effectively substituted by glutamine residues (Figure 2B). In summary, the N1-fragment has a neuroprotective role inside biomolecular LLPS-condensates.
In summary, prion diseases are caused by the misfolding of a normal α-helix-rich PrPC into an abnormal β-sheets-rich PrPSc. PrPC is an RBP and may have a neuroprotective role inside biomolecular condensates. Sequence-specific RBP–RNA interactions in neurons are maintained inside the LLPS-condensates and preserve the protein-RNA recognition code. This code can be used to identify genes/proteins that are post-transcriptionally regulated by the RBP. In the present study, PrPC was 1-L transcribed into a nucleotide sequence and compared with the human transcriptome (BLASTn). The identified genes/proteins were comprehensively reviewed here, and their functions and profile were found to be consistent with prion diseases. However, this study is purely bioinformatic in nature and experimental validation is needed to confirm the in silico predictions.

2. Results and Discussion

The amino acid sequence of PrPC was 1-L transcribed into the four nucleic acid sequences (see Materials and Methods) and then the nucleic acid sequences were applied in BLASTn process screening. 1-L transcription and BLASTn alignments generated both the mRNA sequence (plus/plus strand) and the reverse complementary RNA sequence (plus/minus strand). Protein sequences that were 1-L compatible with a reverse complementary RNA sequence were considered as sequences evolved to recognize regulatory micro-RNAs (miRNAs). These small endogenous RNAs pair and bind to mRNA sites to induce post-transcriptional repression. Reducing the level of miRNAs or other small regulatory RNAs can thus promote translation. Alignment with reverse complement RNA sequences (plus/minus strand) is considered to be promotive (yellow in the figures). In contrast, alignment with the RNA sequence of the gene (plus/plus strand) is considered to be repressive (green in the figures), since the sequestering and blocking of free mRNA by the test protein represses translation. The genes identified according to these alignments are listed in Figure 3 (1-L transcription of N-(AA)n-C sequence) and Figure 4 (1-L transcription of C-(AA)n-N sequence). The main finding of this analysis is that 53.2% of the identified genes/proteins can currently be directly or indirectly associated with the prion diseases discussed in Section 2.1. Genes/proteins that map the relationship between prion protein and mitochondria are discussed in Section 2.2. Genes/proteins that are associated with cancer are discussed in Section 2.3. The genes/proteins that define the relatedness between PrPC and COVID-19 are discussed in Section 2.4. Genes/proteins involved in ER stress and potentially regulated by PrPC are discussed in Section 2.5.
As mentioned in the introductory section, the GGA triplet repeat RNA aptamer (R12) can protect against the misfolding of the normal prion protein (PrPC) into its abnormal form (PrPSc). Years ago, it was shown in experiments with ScN2a cells that R12 binds to the N-terminal half of PrPC and inhibits the formation of PrPSc [13]. This RNA aptamer was used as an example in the introductory section to familiarize the reader with the proposed method of 1-L transcription. The PrPC octa-repeat sequence is 1-L compatible with R12 (Figure 1A). The R12 RNA aptamer is just one example found in the literature that validates the proposed method. The crystal structure of the ribosomal release factor 1 (RF1), which interacts with P-site tRNA (4V63), can be another example that explains the principle of the method (Figure 1B). The presented bioinformatics study using the still-new method of “1-L transcription” identifies genes/proteins associated with prion diseases and the spectrum of genes provides new insight into prion protein function. For example, the GPI signal peptide (GPI-SP) could be an important intracellular regulator in PrPC-producing cells, since the largest group of genes was identified in regions of GPI signal peptide alignment (Figure 3 and Figure 4). Currently, PrPC is recognized mainly as a GPI (glycosylphosphatidyl-inositol)-anchored membrane protein whose α/β/γ/-cleavage or shedding (Figure 2B) leads to extracellular signaling [25,26].

2.1. 1-L Transcription of the Prion Protein and Genes/Proteins Identified as Being Relevant to Prion Diseases

1-L transcript and BLASTn alignments of the human prion protein revealed 47 genes/proteins, of which 53.2% may be directly or indirectly associated with prion diseases (Figure 3 and Figure 4). One example is post-transcriptionally promoted CD44 (Figure 4), which enhances ER stress resistance in a UPR-dependent manner, and also improves longevity [27]. Furthermore, CD44 is expressed in the regions of the brain showing astrocytic prion accumulation [28]. Post-transcriptionally promoted PSME3 (Figure 4), which is the 11S activator of the 20S proteasome catalytic core, may be associated with increased proteasome functionality and with an interaction between 20S proteasomes and prion proteins [29]. The post-transcriptional repression of the dicarboxylate carrier SLC25A10 (Figure 4), which cooperates with the circadian protein CLOCK and regulates rhythmic mitochondrial respiration [30], may be associated with sleep alterations and electroencephalographic changes in sCJD patients [31]. Interestingly, these three genes/proteins show 1-L compatibility with the octa-repeat (Figure 4).
The PrPc α1-β2 region and part of the α2 region have 1-L promoting compatibility with IL1RAP (interleukin 1 receptor accessory protein, Figure 3). Moreover, the IL-1 signaling pathway was proposed as a possible therapeutic target for prion disease, since IL-1R-deficiency significantly delayed the onset of neurodegeneration in mice [32,33]. The PrPc α1-β2 region also showed post-transcriptional promotion of TULP4 (Figure 3), which was listed amongst 52 prion strain-discriminating genes [34].
The PrPc α1-β1 reverse direction showed 1-L repressive compatibility with IL6R (Figure 4, α1-β1). IL-6/IL6R signaling is involved in astrogliosis, which is a hallmark of prion diseases [35]. The same sequence also showed the promotion of the SH2 domain-containing adapter protein SHE (Figure 4), which is an evolutionarily conserved inhibitor of c-Abl kinase [36]. A neurotoxic prion fragment (PrP106-126) has been shown to activate IL6R [35] and c-Abl [37]. c-Abl triggers the upregulation of STK4/MST1 [37], and the GPI-signal sequence of the pro-prion protein showed post-transcriptional repression of STK4/MST1 (Figure 4). However, pro-death STK4/MST1 signaling is activated in prion disease models [37,38]. Hypothetically, when PrP106-126 initiates aggregation, then prion protein in LLPS-condensates is reduced and sequence-specific PrP–RNA interactions are not provided.
The GPI-signal peptide (GPI-SP) sequence showed a repression of mitochondrial SSBP1 (Figure 4), which protects cells from proteotoxic stresses by potentiating the stress-induced transcriptional activity of HSF1. HSF1 is known to confer an important protective function against prion diseases [39]. In contrast, the GPI-SP sequence promotes ZFP36L1/BRF1 (Figure 4), which is an ARE-RBP involved in 3′UTR regulation of mRNA decay [40]. 14-3-3 has a central chaperone-like function [41] and binds to phosphorylated ZFP36L1/BRF1 to inhibit its mRNA decay activity [42]. Increased 14-3-3 expression is a reliable marker of sCJD [43]. The promotion of the importin KPNA5 (Figure 4, GPI-SP) plays a role in IFN-signaling [44], thereby interfering with prion propagation. Moreover, some IFN-stimulated genes might have protective roles in the brain [45]. KPNA5 can also act as a chaperone by shielding aggregation-prone proteins from misfolding, resulting in irreversible phase-transition into insoluble aggregates [46]. Promoted CDKN2C (Figure 4, GPI-SP) binds to CDK4 or CDK6 to reduce CDK activation, thereby controlling the progression of the cell cycle through G1 [47]. Cyclin D1-CDK4/6 activity is generally reduced during the late G1 phase, whereas cyclin E-CDK2 activity increases and promotes the G1/S transition by phosphorylating RB1. Some cancers therefore upregulate CDKN2C expression to activate CDK2 and cell cycle progression [48]. Interestingly, the pathological course of prion disease is characterized by the progressive proliferation of microglial and astrocyte populations [49].
Promoted KATNAL1 (Figure 4, GPI-SP) is a catalytic subunit of the microtubule-severing enzyme katanin. TAU protects microtubules against katanin [50], and the concentration of TAU in the cerebrospinal fluid of CJD patients is markedly increased [51]. Interestingly, PrPc and Aβ peptide may have opposite effects, since 1-L transcription of the Aβ peptide identified post-transcriptional repression of KATNAL1 [3]. Consequently, PrPc misfolding may initiate Aβ accumulation and misfolding. Coexistent amyloid Aβ peptide plaques have been reported in some transmissible spongiform encephalopathies in what could be a widespread phenomenon [52].
Repressed ANKRD28 (Figure 4, GPI-SP) is a scaffolding subunit of the heterotrimeric protein phosphatase PP6 complex (ANKRD28-PP6R1,2-PP6c) [53]. In the Hippo pathway, the PP6 complex is likely to compete with MST1 for binding to MOB1 and for its phosphorylation/dephosphorylation [53]. Differential editing characterized by reverse-frequency alterations between sCJD and a mouse model of epilepsy was observed at the 3′UTR of Ankrd28 [54].
Repressed DAPK2 (Figure 3, α2) is a Ca2+/CaM-regulated serine/threonine kinase that can suppress mTOR activity to induce autophagy [55]. DAPK2 also phosphorylates BECLIN-1, a core protein in the autophagic machinery, leading to the dissociation of its inhibitor, BCL-XL [56]. Autophagy is known to be decreased in scrapie disease [57,58]. Repressed DYM (Figure 3, α3-GPI-SP) is involved in Golgi organization [59], and fragmented Golgi and TGN are observed in CJD [60]. Post-transcriptionally repressed OR6C4 (Figure 3, α3-GPI-SP), which belongs to a large olfactory receptor family, is transcriptionally increased in scrapie [61]. The repressed TF SOX4 (Figure 3, GPI-SP) is a downstream signaling target for the cytokine TGF-β and suppresses TH2 cell–mediated inflammation. During prion infection, SOX4 appears to be transcriptionally downregulated [62].

2.2. The Prion Protein and Mitochodria

As shown in Figure 3 and Figure 4, the GPI-attachment signal peptide of PrPc (GPI-SP) post-transcriptionally regulates an important number of the identified genes/proteins. When expressed as a cytosolic peptide, GPI-SP was observed to localize to the mitochondria and to induce mitochondrial fragmentation and vacuolization. This was followed by the loss of mitochondrial membrane potential, ultimately resulting in apoptosis [63]. PrPC has also been localized to the inner mitochondrial membrane where it appears not to be attached to the membrane via the GPI anchor, but rather inserted into the membrane so that the C-terminus is protected [64]. Recently, a point mutation in GPI-SP was shown to accelerate the development of prion disease [65].
Post-transcriptionally repressed methyltransferase HEMK1 (Figure 3, α3-GPI-SP), which is similar to a bacterial enzyme, is localized in the mitochondria and is therefore known as mitochondrial protein release factor methylation C (MPRMC). HEMK1 methylates the glutamine residue of the GGQ motif of mitochondrial release factors (RFs) [66]. RFs recognize the stop codon and consequently the peptidyl-tRNA bond of the tRNA located in the P-site of the ribosome. The peptidyl-tRNA bond is cleaved to release the newly synthesized protein, thereby terminating mRNA translation. The glutamine (CAA codon) in the universally conserved GGQ motif (Figure 1B) is inserted into the center of the peptidyl transferase. In addition, it recognizes and interacts with the C2452A2451 of rRNA and the A76 of tRNA, and is positioned to contribute directly to peptidyl-tRNA hydrolysis and translation termination [16]. In bacteria, the glutamine methylation of the GGQ motif of RFs by the enzyme PrmC is essential for translational termination and transcript recycling [66]. The GGQ motif and PrPc octa-repeat are 1-L transcribed to GGA RNA (Figure 1), such that the GGA triplet repeat RNA binds PrPC and reduces the PrPSc level [13].
Post-transcriptionally repressed SSBP1 (Figure 4, GPI-SP) is essential for the initiation of mitochondrial DNA replication [67,68]. Post-transcriptionally promoted MTHFD2 (Figure 4, GPI-SP) participates in the mitochondrial part of folate-mediated one-carbon metabolism [69]. Impaired one-carbon metabolism is involved in neurodegeneration [69]. Repressed Hippo kinase STK4/MST1 (Figure 4, GPI-SP) is activated in macrophages during infection. This signaling not only contributes to the anti-microbial process by promoting ROS generation, but also protects macrophages against oxidative stress by limiting the production of ROS [70]. The release of ROS leads to the recruitment of STK4/MST1 from the cytosol to the mitochondrial membrane [70].
Promoted GSTO2 (Figure 3, GPI-SP) exhibits thioltransferase activity, which may have a role in regulating GSH levels [71]. PrPC shows a protective effect during oxidative stress, with the GSH level in PRNP−/− thymocytes being significantly decreased [72]. However, the overexpression of GSTO2 suppresses mitochondrial respiration [71]. Post-transcriptionally repressed dicarboxylate carrier SLC25A10/DIC (Figure 4, octa-repeat), together with SLC25A11 (oxoglutarate carrier), are the main cytoplasmic GSH transporters across the mitochondrial inner membrane [73]. SLC25A10/DIC supports both redox- and energy-homeostasis, significantly improves cell injury and mitochondrial dysfunction and inhibits the mitochondrial apoptosis pathway [74]. Mitochondrial respiration and ROS production show rhythmic activity, while the circadian protein CLOCK regulates cell metabolism via the mitochondrial carrier SLC25A10 [30]. Sleep alterations and electroencephalographic (EEG) changes characterize sCJD [31].

2.3. The Prion Protein and Cancer

A link between PrPC and cancer progression was first reported more than 20 years ago in pancreatic cancer cells [75]. PrPC is now known to be associated with diverse solid cancer types, such as gastric cancer and glioma [76]. The ectopic expression of PrPC in gastric cancer cells was shown to promote cell proliferation and the G1/S transition [77]. Transfection with PrPC increased the transcription of CyclinD1 (CCND1) and CDK4, while CCND1 also increased at the protein level [77]. The present bioinformatics study showed that the 1-L transcription of PrPC (PRPN) leads to the post-transcriptional promotion of CDKN2C and ZFP36L1 (Figure 4, GPI-SP). The cyclin-dependent kinase inhibitor 2C (CDKN2C, INK4C, p18) binds to CDK4/6 and reduces CDK-kinase binding/activation to CCND1, which controls G1-S progression [47]. ZFP36L1 is an ARE-RBP that binds to the 3′UTR to mediate mRNA decay, including the mRNAs for CCND1 [40] and CDK6 [78]. In light of this, both CDKN2C and ZFP36L1 are thought to protect against aberrant cell cycle progression. Nevertheless, the cell cycle is a tightly regulated process, and abnormal progression can be achieved through the upregulation of cell cycle inhibitors. Some cancers upregulate CDKN2C [48], and it has been suggested that ZFP36L1 promotes gastric cancer [79]. Moreover, when PrPC post-transcriptionally inhibits CCND1-CDK4/6, the cell may nevertheless transcriptionally overexpress CCND1-CDK4/6. This may explain why PrPC transfection abnormally increases the transcription of CCND1 and CDK4 genes, leading to abnormal cell cycle progression [77].
SSBP1 suppresses TGF-β-driven EMT by regulating mitochondrial retrograde signaling [80]. However, PrPc post-transcriptionally represses SSBP1 (Figure 4, GPI-SP). The subsequent loss of SSBP1 decreases mitochondrial DNA copy number, thereby activating TGF-β promoter activity [80]. On the other hand, repressed TF SOX4 (Figure 3, GPI-SP) is a downstream signaling target for cytokine TGF-β and is required for TGF-β-induced EMT [81].
Repressed RNA-binding protein RBMS3 (Figure 4, GPI-SP) plays a significant role in many diseases, especially cancer initiation and progression. The absence of RBMS3 activates the Wnt/catenin pathway, with low RBMS3 expression usually correlating with worse prognosis [82], as, for example, in gastric cancer [83]. PrPc post-transcriptionally represses FAM13A (Figure 4, α2-α1), with the reduced level of FAM13A protein leading to accelerated epithelial cell proliferation in murine lungs during the recovery phase after smoking/infection-induced injury [84].
PrPC post-transcriptionally promotes CD44 (Figure 4, octa-repeat). The single CD44 gene codes for a large family of multifunctional, single-chain, transmembrane glycoproteins belonging to the class of cell adhesion molecules (CAMs). CD44 has been recognized as a cancer stem cell marker in several tumor types. The binding of CD44 to its ligands osteopontin (OPN) and hyaluronan (HA) induces stemness and EMT in glioblastomas and breast cancer. In colorectal cancer, OPN and CXCL12 induce CD44v6 expression. The subsequent collaboration between CD44v6, HGF and Met induces EMT [85].
PrPC post-transcriptionally promotes the hedgehog acyltransferase HHAT (Figure 3, α2). This catalyzes the transfer of a palmitoyl lipid to the N-terminal cysteine of Hedgehog (HH) precursor proteins. HH precursor proteins must undergo N-terminal palmitoylation before they can function as HH signaling ligands (Sonic, Desert, and Indian) [86]. The excessive expression of HH signaling molecules (ligand-dependent signaling) may lead to cancer, and several inhibitors of HH signaling pathways have been developed for cancer treatment [87].
PrPC post-transcriptionally represses STK4/MST1 (Figure 4, GPI-SP), resulting in the nuclear localization of YAP/TAZ (Hippo signaling pathway). This interferes with the cell cycle and increases the expression of pro-cancerous genes [88].

2.4. The Prion Protein and COVID-19

Almost 600 million people have been infected with SARS-CoV-2, with approximately half exhibiting some degree of continuing health complications. This is generically referred to as persistent post-COVID syndrome, or long COVID. Up to 35% of all elderly COVID-19 patients also develop mild-to-severe encephalopathy due to complications arising from a SARS-CoV-2-induced cytokine storm [89]. COVID-19 is strongly associated with the symptomology, onset, and development of human prion diseases [89,90,91,92,93].
PrPC post-transcriptionally represses IL6R (Figure 4, α1-β1), which is mostly a membrane-bound receptor. IL-6 activates cells by binding to membrane-bound IL6R and subsequently forming a glycoprotein 130 (gp130) homodimer. Cells that express gp130, but not IL6R, can be activated by IL-6 and soluble IL6R (sIL6R) that is shed from the cell surface. Signaling by the IL-6/sIL6R complex is referred to as “trans-signaling” and promotes the inflammatory response by inducing leukocyte activation and survival, as well as by affecting tissue permeability [94]. Soluble gp130 (sgp130) is present in the blood, and the balance of IL-6, IL-6/sIL6R and IL-6/sIL6R/sgp130 complexes allows simultaneous classic- and trans-signaling [95]. Interestingly, the depletion of cellular cholesterol triggers the shedding of human IL6R by ADAM10 [96]. Previous “1-L transcription” studies showed that SARS-CoV-2 infection reduces cellular cholesterol [4,5]. Moreover, increased IL-6 is a marker of COVID19 [97,98], and may trigger IL-6/sIL6R trans-signaling. Interestingly, this signaling activates vascular inflammatory responses via HIF1α-induced glycolysis. The short-term inhibition of IL6R signaling in COVID-19 patients protects the vasculature from injury, while the persistent inhibition of IL-6 signaling increases the susceptibility to severe complications (bacterial/fungal secondary infections) and is associated with poor outcomes [99]. The protease ADAM10 is responsible for PrPc shedding (Figure 2B) [25], and the shed PrPC post-transcriptionally represses IL6R. Γ-cleavage of PrPC and the consequent N3-fragment signaling (Figure 2B) will also repress IL6R (Figure 4, α1-β1). In addition, PrPC promotes the ZFP36L1 RBP (Figure 4, GPI-SP) that mediates the mRNA decay of HIF1α [40]. In light of this, it appears that PrPC may be upregulated upon SARS-CoV-2 infection to limit excessive signaling by IL-6. The upregulation of PrPC in the presence of PrPSc may cause PrPfibril and exacerbate prion diseases.
PrPC is involved in finely regulating the redox balance. When exposed to oxidative stress, the GSH level in PRNP−/− thymocytes decreases significantly compared to WT thymocytes [72]. The promoted GSTO2 (Figure 3, GPI-SP) exhibits thioltransferase activity, which may have a role in regulating GSH levels [71]. Polymorphisms in GSTO1 and GSTO2 have been associated with laboratory parameters of inflammation in COVID-19 [100,101].
PrPC post-transcriptionally promotes KPNA5 (Figure 4, GPI-SP), which belongs to the importin-α family (IMPα6). TDP-43 and NF-κB are examples of cargo for KPNA5 [46]. KPNA5 also binds and transports STAT1 to the nucleus, which is a key step during IFN-signaling [44]. COVID-19 patients show alterations in KPNA5 [102]. Moreover, ivermectin is a potent inhibitor of SARS-CoV-2 and targets the IMPα component of the IMP α/β1 heterodimer [103].
PrPC post-transcriptionally promotes PSME3 (Figure 4, octa-repeat), which is an activator of the 20S proteasome catalytic core. During viral infections, TLR ligands upregulate the expression of the 11S proteasome subunit PSME3 in macrophages via NF-κB-mediated transcription. PSME3, in turn, enhances the transcriptional activity of NF-κB by directly binding to and destabilizing KLF2, which is a negative regulator of NF-κB transcriptional activity [104]. Interestingly, the upregulation of the proteasome components (including PSME3) was observed in COVID-19 patients with hyperinflammatory conditions [105].
PrPC post-transcriptionally promotes GIGYF2 (Figure 4, α2-β2), which interacts with 4EHP (5′ cap-binding protein) to form the GIGYF2–4EHP translational repressor complex. The SARS-CoV-2 protein NSP2 impairs the silencing capacity of the human 4EHP–GIGYF2 complex [106].

2.5. The Prion Protein and ER Stress

The accumulation of unfolded proteins leads to ER stress. This is followed by an adaptive response via the activation of several pathways including the UPR, PKR-like ER kinase (PERK), inositol-requiring transmembrane kinase/endoribonuclease 1 (IRE1) and activating transcription factor 6 (ATF6). The association between ER stress, UPR and neuropathology is well established, and prolonged ER stress activates apoptosis signaling, leading to neuronal death. Prion diseases were shown to involve mainly the PERK pathway, as well as the IRE1 and ATF6 pathways [107]. Persistent ER stress appears to cause a deficiency of the GPI anchor (ATF6 pathway), which is required for the conversion of pro-prion proteins to GPI-anchored prion proteins [108].
PrPC post-transcriptionally represses JAK1 (Figure 4, GPI-SP), thereby contributing to ER-stress-induced inflammation. JAK1 interacts with and phosphorylates PERK and mediates the ER stress-induced activation of STAT3, leading to IL-6 production [109]. PrPC post-transcriptionally represses SSBP1 (Figure 4, GPI-SP). SSBP1 is a mitochondrial single-stranded DNA-binding protein that protects cells from proteotoxic stresses by increasing the transcriptional activity of stress-induced HSF1. HSF1 recruits SSBP1 to the promoters of genes encoding cytoplasmic, nuclear and mitochondrial chaperones, thereby increasing their transcription [110]. PrPC post-transcriptionally represses RIC8B (Figure 3, α3). This chaperone regulates the folding and cellular abundance of heterotrimeric G protein α subunits, especially Gαs/olf. Olfactory neurons that lack RIC8B, and consequently Gαolf, are more susceptible to cell death [111].
PrPC post-transcriptionally promotes KPNA5 (Figure 4, GPI-SP), the karyopherin subunit alpha 5. In addition to its classical functions in the nuclear import and export of cargo (e.g., TDP-43 and NF-κB), KPNA5 can also act as a chaperone by shielding aggregation-prone proteins against misfolding, accumulation and irreversible phase-transition into insoluble aggregates [46]. PrPC post-transcriptionally promotes SUCO (Figure 4, α2-α1), an ER protein that participates in non-glycoprotein quality control. It does this via the SUCO/SLP1-TAPT1 complex, which binds unfolded proteins and protects them from degradation during folding. In the absence of SUCO, approximately 20–30% of newly synthesized proteins that would otherwise fold are degraded [112]. PrPC post-transcriptionally promotes CD44 (Figure 4, octa-repeat), which increases basal ATF6 activity and ER-stress resistance [27].

3. Materials and Methods

The primary structures of proteins are involved in protein-RNA recognition/interaction. These processes are driven by 1-L and 2-L codes conserved in the amino acid codons (Figure 1). Such codes can be used to identify mRNA and miRNA sequences compatible with genes/proteins that are post-transcriptionally regulated by specific RBPs.

3.1. 1-L Transcription Procedure

The 1-L transcription procedure is relatively simple and involves the amino acid sequence of the specific RBP being transcribed into an RNA sequence based on the nucleotide at the second position of the amino acid codon (1-letter code). The resulting nucleotide sequence is then used for the classical BLASTn screening of the human transcriptome. Reading of the 5’-RNA by the RBP can be carried out in both directions using the amino acid sequence N-(AA)n-C or the reverse amino acid sequence C-(AA)n-N (Figure 1). Hence, the 1-L transcription should be written for two amino acid sequences: one for N-(AA)n-C and the other for C-(AA)n-N. Serine (Ser, S) has two types of codons, one with C (cytidine) at the second position in the amino acid codon and the other with G (guanosine). Thus, two nucleotide sequences are obtained for each amino acid sequence, one with S-C-transcription and the other with S-G-transcription. A total of four nucleotide sequences are obtained (Figure 5).

3.2. BLASTn Screening Process

The BLASTn screening of the human transcriptome was performed as a standard nucleotide blast at NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (accessed on 9 May 2024). This was performed separately for the four nucleotide sequences. The following parameters were used for this search: “Genomic + transcript databases” and “human genomic plus transcript”, “somewhat similar sequences” (blastn), word size = 7, maximum number of target sequences = 500 and expected threshold = 100.

4. Conclusions

Prion diseases are caused by the misfolding of a normal α-helix-rich PrPC into an abnormal β-sheets-rich PrPSc (Figure 2A). PrPC is an RBP (Figure 1A) and in theory may play a neuroprotective role inside biomolecular condensates. The sequence-specific RBP–RNA interactions within neurons are maintained inside LLPS-condensates [9] and preserve the protein-RNA recognition code (Figure 1B) [6,7]. RBPs use at least one amino acid sequence that can be 1-L transcribed into the exact nucleotide sequence of the recognized RNA. This can be used to identify genes/proteins that are post-transcriptionally regulated by the RBP. For example, based on this theory, PrPC recognizes GGA triplet repeats (R12) using its octa-repeat sequence, and interacts with R12 using Lys-rich sequences [13] located on either side of octa-repeat sequence (Figure 1A).
The 1-L transcription of the human prion protein and BLASTn alignments resulted in the identification of a set of genes/proteins (Figure 3 and Figure 4), of which approximately half were directly or indirectly associated with prion diseases (discussed in Section 2.1). Many of the identified genes/proteins were found to be involved/associated with mitochondria (discussed in Section 2.2), cancer (discussed in Section 2.3), COVID-19 (discussed in Section 2.4) and ER stress (discussed in Section 2.5). Furthermore, the GPI-attachment signal peptide (GPI-SP) post-transcriptionally regulates a considerable number of the identified genes/proteins (Figure 3 and Figure 4). For example, promoted KATNAL1 (Figure 4, GPI-SP) is a catalytic subunit of the microtubule-severing enzyme katanin. TAU protects microtubules against katanin [50], and the concentration of TAU in the cerebrospinal fluid of CJD patients is markedly increased [51]. Interestingly, PrPc and Aβ peptide may have opposite effects, since 1-L transcription of the Aβ peptide identified the post-transcriptional repression of KATNAL1 [3]. Consequently, PrPc misfolding may initiate Aβ accumulation and misfolding. Coexistent amyloid Aβ peptide plaques have been reported in some transmissible spongiform encephalopathies in what could be a widespread phenomenon [52].
Interestingly, this method identified the mitochondrial methyltransferase HEMK1 (Figure 3), which methylates the glutamine residue of the GGQ motif of mitochondrial release factors, which is essential for translation termination and transcript recycling [66]. GGQ motif and PrPc octa-repeat are 1-L transcribed to GGA RNA (Figure 1). GGA triplet-repeat RNA was found to reduce the PrPSc level in mouse neuronal cells persistently infected with a transmissible spongiform encephalopathy agent [13]. The same GGQ amino acid motif was proposed for the recognition of ribose in prebiotic history, with ribose being the sugar component of RNA [17].

Funding

This research was funded by VEGA, grant number 2/0064/22.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Nahalka, J. 1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit. Int. J. Mol. Sci. 2024, 25, 4440. [Google Scholar] [CrossRef] [PubMed]
  2. Nahalka, J. 1-L Transcription in Parkinson’s Disease. Front. Biosci. 2023, 28, 292. [Google Scholar] [CrossRef] [PubMed]
  3. Nahalka, J. 1-L Transcription in Alzheimer’s Disease. Curr. Issues Mol. Biol. 2022, 44, 3533–3551. [Google Scholar] [CrossRef]
  4. Nahalka, J. Transcription of the Envelope Protein by 1-L Protein–RNA Recognition Code Leads to Genes/Proteins That Are Relevant to the SARS-CoV-2 Life Cycle and Pathogenesis. Curr. Issues Mol. Biol. 2022, 44, 791–816. [Google Scholar] [CrossRef] [PubMed]
  5. Nahalka, J. Theoretical Analysis of S, M and N Structural Proteins by the Protein–RNA Recognition Code Leads to Genes/proteins that Are Relevant to the SARS-CoV-2 Life Cycle and Pathogenesis. Front. Genet. 2021, 12, 763995. [Google Scholar] [CrossRef]
  6. Nahalka, J. Protein–RNA recognition: Cracking the code. J. Theor. Biol. 2014, 343, 9–15. [Google Scholar] [CrossRef]
  7. Nahalka, J. The role of the protein–RNA recognition code in neurodegeneration. Cell. Mol. Life Sci. 2019, 76, 2043–2058. [Google Scholar] [CrossRef]
  8. Milicevic, K.; Rankovic, B.; Andjus, P.R.; Bataveljic, D.; Milovanovic, D. Emerging Roles for Phase Separation of RNA-Binding Proteins in Cellular Pathology of ALS. Front. Cell Dev. Biol. 2022, 10, 840256. [Google Scholar] [CrossRef]
  9. de Vries, T.; Novakovic, M.; Ni, Y.; Smok, I.; Inghelram, C.; Bikaki, M.; Sarnowski, C.P.; Han, Y.; Emmanouilidis, L.; Padroni, G.; et al. Specific protein-RNA interactions are mostly preserved in biomolecular condensates. Sci. Adv. 2024, 10, eadm7435. [Google Scholar] [CrossRef]
  10. Deleauit, N.R.; Lucassen, R.W.; Supattapone, S. RNA molecules stimulate prion protein conversion. Nature 2003, 425, 717–720. [Google Scholar] [CrossRef]
  11. Derrington, E.; Gabus, C.; Leblanc, P.; Chnaidermann, J.; Grave, L.; Dormont, D.; Swietnicki, W.; Morillas, M.; Marck, D.; Nandi, P.; et al. PrPC has nucleic acid chaperoning properties similar to the nucleocapsid protein of HIV-1. Comptes Rendus. Biol. 2002, 325, 17–23. [Google Scholar] [CrossRef] [PubMed]
  12. Hong, J.-M.; Munna, A.N.; Moon, J.-H.; Kim, J.-H.; Seol, J.-W.; Eo, S.-K.; Park, S.-Y. Antiviral activity of prion protein against Japanese encephalitis virus infection in vitro and in vivo. Virus Res. 2023, 338, 199249. [Google Scholar] [CrossRef] [PubMed]
  13. Mashima, T.; Nishikawa, F.; Kamatari, Y.O.; Fujiwara, H.; Saimura, M.; Nagata, T.; Kodaki, T.; Nishikawa, S.; Kuwata, K.; Katahira, M. Anti-prion activity of an RNA aptamer and its structural basis. Nucleic Acids Res. 2012, 41, 1355–1362. [Google Scholar] [CrossRef] [PubMed]
  14. Mashima, T.; Matsugami, A.; Nishikawa, F.; Nishikawa, S.; Katahira, M. Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein. Nucleic Acids Res. 2009, 37, 6249–6258. [Google Scholar] [CrossRef] [PubMed]
  15. Kamps, J.; Bader, V.; Winklhofer, K.F.; Tatzelt, J. Liquid–liquid phase separation of the prion protein is regulated by the octarepeat domain independently of histidines and copper. J. Biol. Chem. 2024, 300, 107310. [Google Scholar] [CrossRef]
  16. Laurberg, M.; Asahara, H.; Korostelev, A.; Zhu, J.; Trakhanov, S.; Noller, H.F. Structural basis for translation termination on the 70S ribosome. Nature 2008, 454, 852–857. [Google Scholar] [CrossRef]
  17. Nahalka, J.; Hrabarova, E. Prebiotic Peptides Based on the Glycocodon Theory Analyzed with FRET. Life 2021, 11, 380. [Google Scholar] [CrossRef]
  18. Lubecka, E.A.; Hansmann, U.H.E. Early Stages of RNA-Mediated Conversion of Human Prions. J. Phys. Chem. B 2022, 126, 6221–6230. [Google Scholar] [CrossRef]
  19. Aarum, J.; Cabrera, C.P.; Jones, A.T.; Rajendran, S.; Adiutori, R.; Giovannoni, G.; Barnes, M.R.; Malaspina, A.; Sheer, D. Enzymatic degradation of RNA causes widespread protein aggregation in cell and tissue lysates. EMBO Rep. 2020, 21, e49585. [Google Scholar] [CrossRef]
  20. Zerr, I.; Ladogana, A.; Mead, S.; Hermann, P.; Forloni, G.; Appleby, B.S. Creutzfeldt–Jakob disease and other prion diseases. Nat. Rev. Dis. Prim. 2024, 10, 14. [Google Scholar] [CrossRef]
  21. Wang, L.Q.; Zhao, K.; Yuan, H.Y.; Wang, Q.; Guan, Z.; Tao, J.; Li, X.N.; Sun, Y.; Yi, C.W.; Chen, J.; et al. Cryo-EM structure of an amyloid fibril formed by full-length human prion protein. Nat. Struct. Mol. Biol. 2020, 27, 598–602. [Google Scholar] [CrossRef] [PubMed]
  22. Hallinan, G.I.; Ozcan, K.A.; Hoq, R.; Cracco, L.; Vago, F.S.; Bharath, S.R.; Li, D.; Jacobsen, M.; Doud, E.H.; Mosley, A.L.; et al. Cryo-EM structures of prion protein filaments from Gerstmann–Sträussler–Scheinker disease. Acta Neuropathol. 2022, 144, 509–520. [Google Scholar] [CrossRef]
  23. Lakkaraju, A.K.K.; Sorce, S.; Senatore, A.; Nuvolone, M.; Guo, J.; Schwarz, P.; Moos, R.; Pelczar, P.; Aguzzi, A. Glial activation in prion diseases is selectively triggered by neuronal PrPSc. Brain Pathol. 2022, 32, e13056. [Google Scholar] [CrossRef] [PubMed]
  24. Makarava, N.; Safadi, T.; Mychko, O.; Pandit, N.P.; Molesworth, K.; Baiardi, S.; Zhang, L.; Parchi, P.; Baskakov, I.V. Engulfment of viable neurons by reactive microglia in prion diseases. bioRxiv 2024. [Google Scholar] [CrossRef]
  25. Shafiq, M.; Da Vela, S.; Amin, L.; Younas, N.; Harris, D.A.; Zerr, I.; Altmeppen, H.C.; Svergun, D.; Glatzel, M. The prion protein and its ligands: Insights into structure-function relationships. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2022, 1869, 119240. [Google Scholar] [CrossRef]
  26. Kinoshita, T. Biosynthesis and biology of mammalian GPI-anchored proteins. Open Biol. 2020, 10, 190290. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  27. Takasugi, M.; Ohtani, N.; Takemura, K.; Emmrich, S.; Zakusilo, F.T.; Yoshida, Y.; Kutsukake, N.; Mariani, J.N.; Windrem, M.S.; Chandler-Militello, D.; et al. CD44 correlates with longevity and enhances basal ATF6 activity and ER stress resistance. Cell Rep. 2023, 42, 113130. [Google Scholar] [CrossRef]
  28. Bradford, B.M.; Wijaya, C.A.W.; Mabbott, N.A. Discrimination of Prion Strain Targeting in the Central Nervous System via Reactive Astrocyte Heterogeneity in CD44 Expression. Front. Cell. Neurosci. 2019, 13, 411. [Google Scholar] [CrossRef]
  29. Amici, M.; Cecarini, V.; Cuccioloni, M.; Angeletti, M.; Barocci, S.; Rossi, G.; Fioretti, E.; Keller, J.N.; Eleuteri, A.M. Interplay between 20S proteasomes and prion proteins in scrapie disease. J. Neurosci. Res. 2009, 88, 191–201. [Google Scholar] [CrossRef]
  30. Cai, T.; Hua, B.; Luo, D.; Xu, L.; Cheng, Q.; Yuan, G.; Yan, Z.; Sun, N.; Hua, L.; Lu, C. The circadian protein CLOCK regulates cell metabolism via the mitochondrial carrier SLC25A10. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2019, 1866, 1310–1321. [Google Scholar] [CrossRef]
  31. Dossena, S.; Imeri, L.; Mangieri, M.; Garofoli, A.; Ferrari, L.; Senatore, A.; Restelli, E.; Balducci, C.; Fiordaliso, F.; Salio, M.; et al. Mutant Prion Protein Expression Causes Motor and Memory Deficits and Abnormal Sleep Patterns in a Transgenic Mouse Model. Neuron 2008, 60, 598–609. [Google Scholar] [CrossRef] [PubMed]
  32. Schultz, J.; Schwarz, A.; Neidhold, S.; Burwinkel, M.; Riemer, C.; Simon, D.; Kopf, M.; Otto, M.; Baier, M. Role of Interleukin-1 in Prion Disease-Associated Astrocyte Activation. Am. J. Pathol. 2004, 165, 671–678. [Google Scholar] [CrossRef] [PubMed]
  33. Hafner-Bratkovič, I.; Benčina, M.; Fitzgerald, K.A.; Golenbock, D.; Jerala, R. NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity. Cell. Mol. Life Sci. 2012, 69, 4215–4228. [Google Scholar] [CrossRef] [PubMed]
  34. Booth, S.; Bowman, C.; Baumgartner, R.; Dolenko, B.; Sorensen, G.; Robertson, C.; Coulthart, M.; Phillipson, C.; Somorjai, R. Molecular classification of scrapie strains in mice using gene expression profiling. Biochem. Biophys. Res. Commun. 2004, 325, 1339–1345. [Google Scholar] [CrossRef]
  35. Hafiz, F.B.; Brown, D.R. A Model for the Mechanism of Astrogliosis in Prion Disease. Mol. Cell. Neurosci. 2000, 16, 221–232. [Google Scholar] [CrossRef]
  36. Schumacher, J.A.; Wright, Z.A.; Florat, D.R.; Anand, S.K.; Dasyani, M.; Batta, S.P.R.; Laverde, V.; Ferrari, K.; Klimkaite, L.; Bredemeier, N.O.; et al. SH2 domain protein E and ABL signaling regulate blood vessel size. PLOS Genet. 2024, 20, e1010851. [Google Scholar] [CrossRef]
  37. Pan, B.; Yang, L.; Wang, J.; Wang, Y.; Wang, J.; Zhou, X.; Yin, X.; Zhang, Z.; Zhao, D. c-Abl Tyrosine Kinase Mediates Neurotoxic Prion Peptide-Induced Neuronal Apoptosis via Regulating Mitochondrial Homeostasis. Mol. Neurobiol. 2014, 49, 1102–1116. [Google Scholar] [CrossRef]
  38. Shott, R.H.; Majer, A.; Frost, K.L.; Booth, S.A.; Schang, L.M. Activation of pro-survival CaMK4β/CREB and pro-death MST1 signaling at early and late times during a mouse model of prion disease. Virol. J. 2014, 11, 160. [Google Scholar] [CrossRef]
  39. Steele, A.D.; Hutter, G.; Jackson, W.S.; Heppner, F.L.; Borkowski, A.W.; King, O.D.; Raymond, G.J.; Aguzzi, A.; Lindquist, S. Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease. Proc. Natl. Acad. Sci. USA 2008, 105, 13626–13631. [Google Scholar] [CrossRef]
  40. Loh, X.-Y.; Sun, Q.-Y.; Ding, L.-W.; Mayakonda, A.; Venkatachalam, N.; Yeo, M.-S.; Silva, T.C.; Xiao, J.-F.; Doan, N.B.; Said, J.W.; et al. RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling. Cancer Res. 2020, 80, 219–233. [Google Scholar] [CrossRef]
  41. Segal, D.; Maier, S.; Mastromarco, G.J.; Qian, W.W.; Nabeel-Shah, S.; Lee, H.; Moore, G.; Lacoste, J.; Larsen, B.; Lin, Z.-Y.; et al. A central chaperone-like role for 14-3-3 proteins in human cells. Mol. Cell 2023, 83, 974–993. [Google Scholar] [CrossRef] [PubMed]
  42. Benjamin, D.; Schmidlin, M.; Min, L.; Gross, B.; Moroni, C. BRF1 Protein Turnover and mRNA Decay Activity Are Regulated by Protein Kinase B at the Same Phosphorylation Sites. Mol. Cell. Biol. 2006, 26, 9497–9507. [Google Scholar] [CrossRef]
  43. Leitão, M.; Baldeiras, I.; Almeida, M.; Ribeiro, M.; Santos, A.; Tomás, J.; Rocha, S.; Santana, I.; Oliveira, C. Sporadic Creutzfeldt–Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3γ assay. Neuroscience 2016, 322, 398–407. [Google Scholar] [CrossRef] [PubMed]
  44. Xu, W.; Edwards, M.R.; Borek, D.M.; Feagins, A.R.; Mittal, A.; Alinger, J.B.; Berry, K.N.; Yen, B.; Hamilton, J.; Brett, T.J.; et al. Ebola Virus VP24 Targets a Unique NLS Binding Site on Karyopherin Alpha 5 to Selectively Compete with Nuclear Import of Phosphorylated STAT1. Cell Host Microbe 2014, 16, 187–200. [Google Scholar] [CrossRef] [PubMed]
  45. Ishibashi, D.; Homma, T.; Nakagaki, T.; Fuse, T.; Sano, K.; Satoh, K.; Mori, T.; Atarashi, R.; Nishida, N. Type I interferon protects neurons from prions in in vivo models. Brain 2019, 142, 1035–1050. [Google Scholar] [CrossRef]
  46. Pasha, T.; Zatorska, A.; Sharipov, D.; Rogelj, B.; Hortobagyi, T.; Hirth, F. Karyopherin abnormalities in neurodegenerative proteinopathies. Brain 2021, 144, 2915–2932. [Google Scholar] [CrossRef]
  47. Hu, Q.; Huang, T. Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition. Int. J. Mol. Sci. 2023, 24, 8939. [Google Scholar] [CrossRef]
  48. Li, G.-S.; Chen, G.; Liu, J.; Tang, D.; Zheng, J.-H.; Luo, J.; Jin, M.-H.; Lu, H.-S.; Bao, C.-X.; Tian, J.; et al. Clinical significance of cyclin-dependent kinase inhibitor 2C expression in cancers: From small cell lung carcinoma to pan-cancers. BMC Pulm. Med. 2022, 22, 246. [Google Scholar] [CrossRef]
  49. Van Everbroeck, B.; Dewulf, E.; Pals, P.; Lübke, U.; Martin, J.-J.; Cras, P. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol. Aging 2001, 23, 59–64. [Google Scholar] [CrossRef]
  50. Qiang, L.; Yu, W.; Andreadis, A.; Luo, M.; Baas, P.W. Tau Protects Microtubules in the Axon from Severing by Katanin. J. Neurosci. 2006, 26, 3120–3129. [Google Scholar] [CrossRef]
  51. Ermann, N.; Lewczuk, P.; Schmitz, M.; Lange, P.; Knipper, T.; Goebel, S.; Kornhuber, J.; Zerr, I.; Llorens, F. CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD. Ann. Clin. Transl. Neurol. 2018, 5, 883–887. [Google Scholar] [CrossRef] [PubMed]
  52. Cali, I.; Cohen, M.L.; Haïk, S.; Parchi, P.; Giaccone, G.; Collins, S.J.; Kofskey, D.; Wang, H.; McLean, C.A.; Brandel, J.-P.; et al. Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: An international study. Acta Neuropathol. Commun. 2018, 6, 5. [Google Scholar] [CrossRef] [PubMed]
  53. Han, K.-J.; Mikalayeva, V.; Gerber, S.A.; Kettenbach, A.N.; Skeberdis, V.A.; Prekeris, R. Rab40c regulates focal adhesions and PP6 activity by controlling ANKRD28 ubiquitylation. Life Sci. Alliance 2022, 5, e202101346. [Google Scholar] [CrossRef] [PubMed]
  54. Kanata, E.; Llorens, F.; Dafou, D.; Dimitriadis, A.; Thüne, K.; Xanthopoulos, K.; Bekas, N.; Espinosa, J.C.; Schmitz, M.; Marín-Moreno, A.; et al. RNA editing alterations define manifestation of prion diseases. Proc. Natl. Acad. Sci. USA 2019, 116, 19727–19735. [Google Scholar] [CrossRef]
  55. Ber, Y.; Shiloh, R.; Gilad, Y.; Degani, N.; Bialik, S.; Kimchi, A. DAPK2 is a novel regulator of mTORC1 activity and autophagy. Cell Death Differ. 2014, 22, 465–475. [Google Scholar] [CrossRef]
  56. Shiloh, R.; Gilad, Y.; Ber, Y.; Eisenstein, M.; Aweida, D.; Bialik, S.; Cohen, S.; Kimchi, A. Non-canonical activation of DAPK2 by AMPK constitutes a new pathway linking metabolic stress to autophagy. Nat. Commun. 2018, 9, 1759. [Google Scholar] [CrossRef]
  57. López-Pérez, O.; Otero, A.; Filali, H.; Sanz-Rubio, D.; Toivonen, J.M.; Zaragoza, P.; Badiola, J.J.; Bolea, R.; Martín-Burriel, I. Dysregulation of autophagy in the central nervous system of sheep naturally infected with classical scrapie. Sci. Rep. 2019, 9, 1911. [Google Scholar] [CrossRef]
  58. López-Pérez, O.; Toivonen, J.M.; Otero, A.; Solanas, L.; Zaragoza, P.; Badiola, J.J.; Osta, R.; Bolea, R.; Martín-Burriel, I. Impairment of autophagy in scrapie-infected transgenic mice at the clinical stage. Mod. Pathol. 2020, 100, 52–63. [Google Scholar] [CrossRef]
  59. Osipovich, A.B.; Jennings, J.L.; Lin, Q.; Link, A.J.; Ruley, H.E. Dyggve–Melchior–Clausen syndrome: Chondrodysplasia resulting from defects in intracellular vesicle traffic. Proc. Natl. Acad. Sci. USA 2008, 105, 16171–16176. [Google Scholar] [CrossRef]
  60. Sakurai, A.; Okamoto, K.; Fujita, Y.; Nakazato, Y.; Wakabayashi, K.; Takahashi, H.; Gonatas, N.K. Fragmentation of the Golgi apparatus of the ballooned neurons in patients with corticobasal degeneration and Creutzfeldt-Jakob disease. Acta Neuropathol. 2000, 100, 270–274. [Google Scholar] [CrossRef]
  61. Gossner, A.G.; Hopkins, J. Transcriptome analysis of CNS immediately before and after the detection of PrPSc in SSBP/1 sheep scrapie. Veter. Microbiol. 2014, 173, 201–207. [Google Scholar] [CrossRef] [PubMed]
  62. Julius, C.; Hutter, G.; Wagner, U.; Seeger, H.; Kana, V.; Kranich, J.; Klöhn, P.; Weissmann, C.; Miele, G.; Aguzzi, A. Transcriptional stability of cultured cells upon prion infection. J. Mol. Biol. 2008, 375, 1222–1233. [Google Scholar] [CrossRef]
  63. Guizzunti, G.; Zurzolo, C. Cytosolically expressed PrP GPI-signal peptide interacts with mitochondria. Commun. Integr. Biol. 2015, 8, e1036206. [Google Scholar] [CrossRef]
  64. Faris, R.; Moore, R.A.; Ward, A.; Race, B.; Dorward, D.W.; Hollister, J.R.; Fischer, E.R.; Priola, S.A. Cellular prion protein is present in mitochondria of healthy mice. Sci. Rep. 2017, 7, 41556. [Google Scholar] [CrossRef]
  65. Kobayashi, A.; Hirata, T.; Shimazaki, T.; Munesue, Y.; Aoshima, K.; Kimura, T.; Nio-Kobayashi, J.; Hasebe, R.; Takeuchi, A.; Matsuura, Y.; et al. A point mutation in GPI-attachment signal peptide accelerates the development of prion disease. Acta Neuropathol. 2023, 145, 637–650. [Google Scholar] [CrossRef] [PubMed]
  66. Fang, Q.; Kimura, Y.; Shimazu, T.; Suzuki, T.; Yamada, A.; Dohmae, N.; Iwasaki, S.; Shinkai, Y. Mammalian HEMK1 methylates glutamine residue of the GGQ motif of mitochondrial release factors. Sci. Rep. 2022, 12, 4104. [Google Scholar] [CrossRef]
  67. Rossmann, M.P.; Dubois, S.M.; Agarwal, S.; Zon, L.I. Mitochondrial function in development and disease. Dis. Model. Mech. 2021, 14, dmm048912. [Google Scholar] [CrossRef]
  68. Jiang, M.; Xie, X.; Zhu, X.; Jiang, S.; Milenkovic, D.; Misic, J.; Shi, Y.; Tandukar, N.; Li, X.; Atanassov, I.; et al. The mitochondrial single-stranded DNA binding protein is essential for initiation of mtDNA replication. Sci. Adv. 2021, 7, eabf8631. [Google Scholar] [CrossRef] [PubMed]
  69. Coppedè, F. One-carbon epigenetics and redox biology of neurodegeneration. Free. Radic. Biol. Med. 2020, 170, 19–33. [Google Scholar] [CrossRef]
  70. Wang, P.; Geng, J.; Gao, J.; Zhao, H.; Li, J.; Shi, Y.; Yang, B.; Xiao, C.; Linghu, Y.; Sun, X.; et al. Macrophage achieves self-protection against oxidative stress-induced ageing through the Mst-Nrf2 axis. Nat. Commun. 2019, 10, 755. [Google Scholar] [CrossRef]
  71. Sumiya, R.; Terayama, M.; Hagiwara, T.; Nakata, K.; Sekihara, K.; Nagasaka, S.; Miyazaki, H.; Igari, T.; Yamada, K.; Kawamura, Y.I. Loss of GSTO2 contributes to cell growth and mitochondria function via the p38 signaling in lung squamous cell carcinoma. Cancer Sci. 2021, 113, 195–204. [Google Scholar] [CrossRef] [PubMed]
  72. Zhang, B.; Shen, P.; Yin, X.; Dai, Y.; Ding, M.; Cui, L. Expression and functions of cellular prion proteins in immunocytes. Scand. J. Immunol. 2020, 91, e12854. [Google Scholar] [CrossRef] [PubMed]
  73. Lash, L.H. Mitochondrial glutathione transport: Physiological, pathological and toxicological implications. Chem. Interact. 2006, 163, 54–67. [Google Scholar] [CrossRef]
  74. Ma, S.; Song, Y.; Xu, Y.; Wang, C.; Yang, Y.; Zheng, Y.; Lu, Q.; Chen, Q.; Wu, J.; Wang, B.; et al. Mild Therapeutic Hypothermia Alleviated Myocardial Ischemia/Reperfusion Injury via Targeting SLC25A10 to Suppress Mitochondrial Apoptosis. J. Cardiovasc. Transl. Res. 2024, 17, 946–958. [Google Scholar] [CrossRef] [PubMed]
  75. Han, H.; Bearss, D.J.; Browne, L.W.; Calaluce, R.; Nagle, R.B.; Von Hoff, D.D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002, 62, 2890–2896. [Google Scholar] [PubMed]
  76. Nahed, R.A.; Safwan-Zaiter, H.; Gemy, K.; Lyko, C.; Boudaud, M.; Desseux, M.; Marquette, C.; Barjat, T.; Alfaidy, N.; Benharouga, M. The Multifaceted Functions of Prion Protein (PrPC) in Cancer. Cancers 2023, 15, 4982. [Google Scholar] [CrossRef]
  77. Liang, J.; Pan, Y.; Zhang, D.; Guo, C.; Shi, Y.; Wang, J.; Chen, Y.; Wang, X.; Liu, J.; Guo, X.; et al. Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. FASEB J. 2007, 21, 2247–2256. [Google Scholar] [CrossRef]
  78. Chen, M.-T.; Dong, L.; Zhang, X.-H.; Yin, X.-L.; Ning, H.-M.; Shen, C.; Su, R.; Li, F.; Song, L.; Ma, Y.-N.; et al. ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6. Sci. Rep. 2015, 5, 16229. [Google Scholar] [CrossRef]
  79. Ding, K.; Zhang, F.; Qi, G.; Lin, M.L.; Chen, M.; Chen, Y.; Zheng, J.; Zhou, F. ZFP36L1 Promotes Gastric Cancer Progression via Regulating JNK and p38 MAPK Signaling Pathways. Recent Patents Anti-Cancer Drug Discov. 2023, 18, 80–91. [Google Scholar] [CrossRef]
  80. Jiang, H.-L.; Sun, H.-F.; Gao, S.-P.; Li, L.-D.; Huang, S.; Hu, X.; Liu, S.; Wu, J.; Shao, Z.-M.; Jin, W. SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling. Cancer Res. 2016, 76, 952–964. [Google Scholar] [CrossRef]
  81. Tiwari, N.; Tiwari, V.K.; Waldmeier, L.; Balwierz, P.J.; Arnold, P.; Pachkov, M.; Meyer-Schaller, N.; Schübeler, D.; van Nimwegen, E.; Christofori, G. Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming. Cancer Cell 2013, 23, 768–783. [Google Scholar] [CrossRef] [PubMed]
  82. Górnicki, T.; Lambrinow, J.; Mrozowska, M.; Podhorska-Okołów, M.; Dzięgiel, P.; Grzegrzółka, J. Role of RBMS3 Novel Potential Regulator of the EMT Phenomenon in Physiological and Pathological Processes. Int. J. Mol. Sci. 2022, 23, 10875. [Google Scholar] [CrossRef] [PubMed]
  83. Zhang, T.; Wu, Y.; Fang, Z.; Yan, Q.; Zhang, S.; Sun, R.; Khaliq, J.; Li, Y. Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer. Am. J. Cancer Res. 2016, 6, 2679–2689. [Google Scholar] [PubMed]
  84. Gong, L.; Bates, S.; Li, Y.; Lin, X.; Wei, W.; Zhou, X. AKT Phosphorylates FAM13A and Promotes Its Degradation via CUL4A/DDB1/DCAF1 E3 Complex. Am. J. Respir. Cell Mol. Biol. 2023, 68, 577–590. [Google Scholar] [CrossRef]
  85. Morath, I.; Hartmann, T.; Orian-Rousseau, V. CD44: More than a mere stem cell marker. Int. J. Biochem. Cell Biol. 2016, 81, 166–173. [Google Scholar] [CrossRef]
  86. Jiang, Y.; Benz, T.L.; Long, S.B. Substrate and product complexes reveal mechanisms of Hedgehog acylation by HHAT. Science 2021, 372, 1215–1219. [Google Scholar] [CrossRef]
  87. Skoda, A.M.; Simovic, D.; Karin, V.; Kardum, V.; Vranic, S.; Serman, L. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn. J. Basic Med. Sci. 2018, 18, 8–20. [Google Scholar] [CrossRef]
  88. Xiao, Y.; Dong, J. The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective. Cancers 2021, 13, 6214. [Google Scholar] [CrossRef]
  89. Lukiw, W.J.; Jaber, V.R.; Pogue, A.I.; Zhao, Y. SARS-CoV-2 Invasion and Pathological Links to Prion Disease. Biomolecules 2022, 12, 1253. [Google Scholar] [CrossRef]
  90. Colaizzo, E.; Prosperini, L.; Petrucci, A.; Perna, A. Creutzfeldt–Jakob disease associated with E200K mutation and SARS-CoV-2 infection: Pure coincidence or neurodegenerative acceleration? Clin. Transl. Neurosci. 2024, 8, 16. [Google Scholar] [CrossRef]
  91. Classen, B. Possible treatments for COVID vaccine induced prion disease. Recent Adv. Clin. Trials 2023, 5, 1–5. [Google Scholar]
  92. Stefano, G.B.; Buttiker, P.; Weissenberger, S.; Anders, M.; Raboch, J.; Ptacek, R.; Kream, R.M. Potential prion involvement in long COVID-19 neuropathology, including behavior. Cell. Mol. Neurobiol. 2023, 43, 2621–2626. [Google Scholar] [CrossRef]
  93. Zhao, Y.; Jaber, V.R.; Lukiw, W.J. SARS-CoV-2, long COVID, prion disease and neurodegeneration. Front. Neurosci. 2022, 16, 1002770. [Google Scholar] [CrossRef] [PubMed]
  94. Liu, X.; Jones, G.W.; Choy, E.H.; Jones, S.A. The biology behind interleukin-6 targeted interventions. Curr. Opin. Rheumatol. 2016, 28, 152–160. [Google Scholar] [CrossRef]
  95. Baran, P.; Hansen, S.; Waetzig, G.H.; Akbarzadeh, M.; Lamertz, L.; Huber, H.J.; Ahmadian, M.R.; Moll, J.M.; Scheller, J. The balance of interleukin (IL)-6, IL-6 center dot soluble IL-6 receptor (sIL-6R), and IL-6 center dot sIL-6R center dot sgp130 complexes allows simultaneous classic and trans-signaling. J. Biol. Chem. 2018, 293, 6762–6775. [Google Scholar] [CrossRef] [PubMed]
  96. Matthews, V.; Schuster, B.; Schütze, S.; Bussmeyer, I.; Ludwig, A.; Hundhausen, C.; Sadowski, T.; Saftig, P.; Hartmann, D.; Kallen, K.-J.; et al. Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 2003, 278, 38829–38839. [Google Scholar] [CrossRef]
  97. Broman, N.; Rantasärkkä, K.; Feuth, T.; Valtonen, M.; Waris, M.; Hohenthal, U.; Rintala, E.; Karlsson, A.; Marttila, H.; Peltola, V.; et al. IL-6 and other biomarkers as predictors of severity in COVID-19. Ann. Med. 2021, 53, 410–412. [Google Scholar] [CrossRef]
  98. Wang, C.; Fei, D.; Li, X.; Zhao, M.; Yu, K. IL-6 may be a good biomarker for earlier detection of COVID-19 progression. Intensiv. Care Med. 2020, 46, 1475–1476. [Google Scholar] [CrossRef] [PubMed]
  99. Kimmig, L.M.; Wu, D.; Gold, M.; Pettit, N.N.; Pitrak, D.; Mueller, J.; Husain, A.N.; Mutlu, E.A.; Mutlu, G.M. IL-6 inhibition in critically Ill COVID-19 patients is associated with increased secondary infections. Front. Med. 2020, 7, 583897. [Google Scholar] [CrossRef]
  100. Djukic, T.; Stevanovic, G.; Coric, V.; Bukumiric, Z.; Pljesa-Ercegovac, M.; Matic, M.; Jerotic, D.; Todorovic, N.; Asanin, M.; Ercegovac, M.; et al. GSTO1, GSTO2 and ACE2 Polymorphisms Modify Susceptibility to Developing COVID-19. J. Pers. Med. 2022, 12, 458. [Google Scholar] [CrossRef]
  101. Djukić, T.; Stevanović, G.; Ćorić, V.; Bukumirić, Z.; Plješa-Ercegovac, M.; Matić, M.; Jerotić, D.; Ašanin, M.; Ercegovac, M.; Ranin, J.; et al. The association of glutathione transferase omega polymorphisms with laboratory inflammatory parameters in COVID-19. Med. Istraz. 2022, 55, 59–66. [Google Scholar] [CrossRef]
  102. Segatori, V.I.; Garona, J.; Caligiuri, L.G.; Bizzotto, J.; Lavignolle, R.; Toro, A.; Sanchis, P.; Spitzer, E.; Krolewiecki, A.; Gueron, G.; et al. Effect of Ivermectin and Atorvastatin on nuclear localization of importin alpha and drug target expression profiling in host cells from nasopharyngeal swabs of SARS-CoV-2- positive patients. Viruses 2021, 13, 2084. [Google Scholar] [CrossRef] [PubMed]
  103. Zaidi, A.K.; Dehgani-Mobaraki, P. The mechanisms of action of ivermectin against SARS-CoV-2—An extensive review. J. Antibiot. 2021, 75, 60–71. [Google Scholar] [CrossRef] [PubMed]
  104. Sun, J.; Luan, Y.; Xiang, D.; Tan, X.; Chen, H.; Deng, Q.; Zhang, J.; Chen, M.; Huang, H.; Wang, W.; et al. The 11S proteasome subunit PSME3 is a positive feedforward regulator of NF-κB and important for host defense against bacterial pathogens. Cell Rep. 2016, 14, 737–749. [Google Scholar] [CrossRef]
  105. Alfaro, E.; Díaz-García, E.; García-Tovar, S.; Zamarrón, E.; Mangas, A.; Galera, R.; López-Collazo, E.; García-Rio, F.; Cubillos-Zapata, C. Upregulated proteasome subunits in COVID-19 patients: A link with hypoxemia, lymphopenia and inflammation. Biomolecules 2022, 12, 442. [Google Scholar] [CrossRef]
  106. Zou, L.; Moch, C.; Graille, M.; Chapat, C. The SARS-CoV-2 protein NSP2 impairs the silencing capacity of the human 4EHP-GIGYF2 complex. iScience 2022, 25, 104646. [Google Scholar] [CrossRef]
  107. Ghemrawi, R.; Khair, M. Endoplasmic reticulum stress and unfolded protein response in neurodegenerative diseases. Int. J. Mol. Sci. 2020, 21, 6127. [Google Scholar] [CrossRef] [PubMed]
  108. Li, J.; Li, S.; Yu, S.; Yang, J.; Ke, J.; Li, H.; Chen, H.; Lu, M.; Sy, M.-S.; Gao, Z.; et al. Persistent ER stress causes GPI anchor deficit to convert a GPI-anchored prion protein into pro-PrP via the ATF6–miR449c-5p–PIGV axis. J. Biol. Chem. 2023, 299, 104982. [Google Scholar] [CrossRef]
  109. Meares, G.P.; Liu, Y.; Rajbhandari, R.; Qin, H.; Nozell, S.E.; Mobley, J.A.; Corbett, J.A.; Benveniste, E.N. PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation. Mol. Cell. Biol. 2014, 34, 3911–3925. [Google Scholar] [CrossRef]
  110. Tan, K.; Fujimoto, M.; Takii, R.; Takaki, E.; Hayashida, N.; Nakai, A. Mitochondrial SSBP1 protects cells from proteotoxic stresses by potentiating stress-induced HSF1 transcriptional activity. Nat. Commun. 2015, 6, 6580. [Google Scholar] [CrossRef]
  111. Machado, C.F.; Nagai, M.H.; Lyra, C.S.; Reis-Silva, T.M.; Machado, A.M.; Glezer, I.; Felicio, L.F.; Malnic, B. Conditional deletion of Ric-8b in olfactory sensory neurons leads to olfactory impairment. J. Neurosci. 2017, 37, 12202–12213. [Google Scholar] [CrossRef] [PubMed]
  112. Zhang, S.; Xu, C.; Larrimore, K.E.; Ng, D.T. Slp1-Emp65: A guardian factor that protects folding polypeptides from promiscuous degradation. Cell 2017, 171, 346–357.e12. [Google Scholar] [CrossRef] [PubMed]
Ijms 25 09961 g001
Figure 1. A theoretical protein–RNA recognition code. (A) GGA triplet repeat RNA (R12) in complex with Lys-rich 2 peptide of the prion protein. RNA aptamer forms a dimer and each monomer binds one Lys-rich 2 peptide. The tryptophan residues (TGG codon) are oriented to the guanosine core (magenta color) and asparagine residues (AAT codon) to adenines (blue color). The 1-L transcription of the octa-repeats is compatible with the GGA triplet repeat RNA. (B) The ribosomal release factor 1 (RF1) interacting with P-site tRNA. 1-L, one-letter code—second nucleotide in codons; 2-L, two-letter code—first two nucleotides in codons [6]. At a shorter distance, proline 227 (P) and glutamine 230 (Q) recognize terminal CCA3′ nucleotide sequence using the 2-L code; at a longer distance, asparagine 233 (N), threonine 234 (T) and T235 recognize terminal CCA3′ nucleotide sequence using 1-L code in the reversed mode. Interestingly, these two sequences are spaced with glycine (G) and valine (V) which can be 2-L transcribed to the complementary sequence GGU5′. The coordinates were downloaded from Protein Data Bank; 2RSK (A) and 4V63 (B) are the corresponding PDB codes, and Visual Molecular Dynamics (VMD 1.9.3) was used for the visualization.
Figure 1. A theoretical protein–RNA recognition code. (A) GGA triplet repeat RNA (R12) in complex with Lys-rich 2 peptide of the prion protein. RNA aptamer forms a dimer and each monomer binds one Lys-rich 2 peptide. The tryptophan residues (TGG codon) are oriented to the guanosine core (magenta color) and asparagine residues (AAT codon) to adenines (blue color). The 1-L transcription of the octa-repeats is compatible with the GGA triplet repeat RNA. (B) The ribosomal release factor 1 (RF1) interacting with P-site tRNA. 1-L, one-letter code—second nucleotide in codons; 2-L, two-letter code—first two nucleotides in codons [6]. At a shorter distance, proline 227 (P) and glutamine 230 (Q) recognize terminal CCA3′ nucleotide sequence using the 2-L code; at a longer distance, asparagine 233 (N), threonine 234 (T) and T235 recognize terminal CCA3′ nucleotide sequence using 1-L code in the reversed mode. Interestingly, these two sequences are spaced with glycine (G) and valine (V) which can be 2-L transcribed to the complementary sequence GGU5′. The coordinates were downloaded from Protein Data Bank; 2RSK (A) and 4V63 (B) are the corresponding PDB codes, and Visual Molecular Dynamics (VMD 1.9.3) was used for the visualization.
Ijms 25 09961 g001
Ijms 25 09961 g002
Figure 2. The prion protein. (A) Misfolding of the prion protein (PrPc) into PrPSc. Misfolded PrPSc forms self-replicating protofibril (PrPfibril) core. PrPfibril templates the native PrPC form into PrPSc form and forms detergent/protease-resistant amyloid fibrils/aggregates/plaques in vivo. (B) Schematic domain representation of the prion protein and its α/β/γ-cleavage and shedding.
Figure 2. The prion protein. (A) Misfolding of the prion protein (PrPc) into PrPSc. Misfolded PrPSc forms self-replicating protofibril (PrPfibril) core. PrPfibril templates the native PrPC form into PrPSc form and forms detergent/protease-resistant amyloid fibrils/aggregates/plaques in vivo. (B) Schematic domain representation of the prion protein and its α/β/γ-cleavage and shedding.
Ijms 25 09961 g002
Ijms 25 09961 g003
Figure 3. Identified genes/proteins via 1-L transcription of N-(AA)n-C sequence. The found sequences are colored according to the schematic domain architecture of the prion protein. α = alpha-helical domains (red, light green, magenta), β = beta-sheet stretches (yellow), 5 x octa-repeat sequence (blue) and GPI-signal sequence (cyan). A GPI (glycosylphosphatidylinositol) anchor is added at AA 230 as a post-translational modification. An LLPS core means that the main sequence participated in liquid–liquid phase separation. The green gene highlights show alignments with the gene transcript RNA sequence (post-transcriptionally repressed) and yellow gene highlights show alignments with the reverse complement RNA sequences (post-transcriptionally promoted). The identified genes/proteins can be directly (●) or indirectly (●) linked to prion diseases.
Figure 3. Identified genes/proteins via 1-L transcription of N-(AA)n-C sequence. The found sequences are colored according to the schematic domain architecture of the prion protein. α = alpha-helical domains (red, light green, magenta), β = beta-sheet stretches (yellow), 5 x octa-repeat sequence (blue) and GPI-signal sequence (cyan). A GPI (glycosylphosphatidylinositol) anchor is added at AA 230 as a post-translational modification. An LLPS core means that the main sequence participated in liquid–liquid phase separation. The green gene highlights show alignments with the gene transcript RNA sequence (post-transcriptionally repressed) and yellow gene highlights show alignments with the reverse complement RNA sequences (post-transcriptionally promoted). The identified genes/proteins can be directly (●) or indirectly (●) linked to prion diseases.
Ijms 25 09961 g003
Ijms 25 09961 g004
Figure 4. Identified genes/proteins via 1-L transcription of C-(AA)n-N sequence. The found sequences are colored according to the schematic domain architecture of prion protein. α = alpha-helical domains (magenta, light green, red), β = beta-sheet stretches (yellow), 5 x octa-repeat sequence (blue) and GPI-signal sequence (cyan). A GPI (glycosylphosphati-dylinositol) anchor is added at AA 230 as a post-translational modification. An LLPS core means that the main sequence participated in liquid–liquid phase separation. Green highlights show alignments with the gene transcript RNA sequence (post-transcriptionally repressed) and yellow highlights show alignments with the reverse complement RNA sequences (post-transcriptionally promoted). The identified genes/proteins can be directly (●) or indirectly (●) linked to prion diseases.
Figure 4. Identified genes/proteins via 1-L transcription of C-(AA)n-N sequence. The found sequences are colored according to the schematic domain architecture of prion protein. α = alpha-helical domains (magenta, light green, red), β = beta-sheet stretches (yellow), 5 x octa-repeat sequence (blue) and GPI-signal sequence (cyan). A GPI (glycosylphosphati-dylinositol) anchor is added at AA 230 as a post-translational modification. An LLPS core means that the main sequence participated in liquid–liquid phase separation. Green highlights show alignments with the gene transcript RNA sequence (post-transcriptionally repressed) and yellow highlights show alignments with the reverse complement RNA sequences (post-transcriptionally promoted). The identified genes/proteins can be directly (●) or indirectly (●) linked to prion diseases.
Ijms 25 09961 g004
Ijms 25 09961 g005
Figure 5. 1-L transcription method. A schematic diagram that visually represents the steps and concept.
Figure 5. 1-L transcription method. A schematic diagram that visually represents the steps and concept.
Ijms 25 09961 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nahalka, J. 1-L Transcription in Prion Diseases. Int. J. Mol. Sci. 2024, 25, 9961. https://doi.org/10.3390/ijms25189961

AMA Style

Nahalka J. 1-L Transcription in Prion Diseases. International Journal of Molecular Sciences. 2024; 25(18):9961. https://doi.org/10.3390/ijms25189961

Chicago/Turabian Style

Nahalka, Jozef. 2024. "1-L Transcription in Prion Diseases" International Journal of Molecular Sciences 25, no. 18: 9961. https://doi.org/10.3390/ijms25189961

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop